Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study

被引：23

作者：

Accurso, Vincenzo ^{[1
]}

Santoro, Marco ^{[2
]}

Raso, Simona ^{[2
]}

Contrino, Angelo Davide ^{[1
]}

Casimiro, Paolo ^{[1
]}

Di Piazza, Florinda ^{[2
]}

Perez, Alessandro ^{[2
]}

Russo, Antonio ^{[2
]}

Siragusa, Sergio ^{[1
]}

机构：

[1] Univ Hosp Policlin Paolo Giaccone, Div Hematol, Via Vespro 129, I-90127 Palermo, Italy

[2] Univ Palermo, Dept Surg Oncol & Stomatol Disciplines, Palermo, Italy

来源：

HEMATOLOGY REPORTS | 2019年 / 11卷 / 04期

关键词：

Splenomegaly; Polycythemia Vera; essential thrombocythemia; INTERNATIONAL WORKING GROUP; PRIMARY MYELOFIBROSIS; AVAILABLE THERAPY; PREDICT SURVIVAL; RUXOLITINIB; THROMBOSIS; NEOPLASMS; SCORE; CLASSIFICATION; VALIDATION;

D O I：

10.4081/hr.2019.8281

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with these diseases. We aimed to study the impact that such alteration has on thrombotic risk and on the survival of patients with essential thrombocythemia and patients with Polycythemia Vera (PV). We studied the relationship between splenomegaly (and its grade), thrombosis and survival in 238 patients with et and 165 patients with PV followed at our center between January 1997 and May 2019.

引用

页码：95 / 97

页数：3

共 20 条

[1] Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients [J].

Andriani, Alessandro ;

Latagliata, Roberto ;

Anaclerico, Barbara ;

Spadea, Antonio ;

Rago, Angela ;

Di Veroli, Ambra ;

Spirito, Francesca ;

Porrini, Raffaele ;

De Muro, Marianna ;

Leonetti, Sabrina Crescenzi ;

Villiva, Nicoletta ;

De Gregoris, Cinzia ;

Montefusco, Enrico ;

Polverelli, Nicola ;

Santoro, Cristina ;

Breccia, Massimo ;

Cimino, Giuseppe ;

Majolino, Ignazio ;

Mazzucconi, Maria Gabriella ;

Vianelli, Nicola ;

Alimena, Giuliana ;

Montanaro, Marco ;

Palandri, Francesca .

AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (03) :318-321

[2] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[3] The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion [J].

Barbui, Tiziano ;

Thiele, Jurgen ;

Gisslinger, Heinz ;

Kvasnicka, Hans Michael ;

Vannucchi, Alessandro M. ;

Guglielmelli, Paola ;

Orazi, Attilio ;

Tefferi, Ayalew .

BLOOD CANCER JOURNAL, 2018, 8 :15

[4] Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) [J].

Barbui, Tiziano ;

Finazzi, Guido ;

Carobbio, Alessandra ;

Thiele, Juergen ;

Passamonti, Francesco ;

Rumi, Elisa ;

Ruggeri, Marco ;

Rodeghiero, Francesco ;

Randi, Maria Luigia ;

Bertozzi, Irene ;

Gisslinger, Heinz ;

Buxhofer-Ausch, Veronika ;

De Stefano, Valerio ;

Betti, Silvia ;

Rambaldi, Alessandro ;

Vannucchi, Alessandro M. ;

Tefferi, Ayalew .

BLOOD, 2012, 120 (26) :5128-5133

[5] Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet [J].

Barbui, Tiziano ;

Barosi, Giovanni ;

Birgegard, Gunnar ;

Cervantes, Francisco ;

Finazzi, Guido ;

Griesshammer, Martin ;

Harrison, Claire ;

Hasselbalch, Hans Carl ;

Hehlmann, Rudiger ;

Hoffman, Ronald ;

Kiladjian, Jean-Jacques ;

Kroeger, Nicolaus ;

Mesa, Ruben ;

McMullin, Mary F. ;

Pardanani, Animesh ;

Passamonti, Francesco ;

Vannucchi, Alessandro M. ;

Reiter, Andreas ;

Silver, Richard T. ;

Verstovsek, Srdan ;

Tefferi, Ayalew .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) :761-770

[6] Prognosis of Primary Myelofibrosis in the Genomic Era [J].

Bose, Prithviraj ;

Verstovsek, Srdan .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 :S105-S113

[7] Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib [J].

Bryan, Jeffrey C. ;

Verstovsek, Srdan .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) :1125-1142

[8] Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients [J].

Cerquozzi, S. ;

Barraco, D. ;

Lasho, T. ;

Finke, C. ;

Hanson, C. A. ;

Ketterling, R. P. ;

Pardanani, A. ;

Gangat, N. ;

Tefferi, A. .

BLOOD CANCER JOURNAL, 2017, 7

[9] Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis [J].

Cervantes, Francisco ;

Vannucchi, Alessandro M. ;

Kiladjian, Jean-Jacques ;

Al-Ali, Haifa Kathrin ;

Sirulnik, Andres ;

Stalbovskaya, Viktoriya ;

McQuitty, Mari ;

Hunter, Deborah S. ;

Levy, Richard S. ;

Passamonti, Francesco ;

Barbui, Tiziano ;

Barosi, Giovanni ;

Harrison, Claire N. ;

Knoops, Laurent ;

Gisslinger, Heinz .

BLOOD, 2013, 122 (25) :4047-4053

[10] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment [J].

Cervantes, Francisco ;

Dupriez, Brigitte ;

Pereira, Arturo ;

Passamonti, Francesco ;

Reilly, John T. ;

Morra, Enrica ;

Vannucchi, Alessandro M. ;

Mesa, Ruben A. ;

Demory, Jean-Loup ;

Barosi, Giovanni ;

Rumi, Elisa ;

Tefferi, Ayalew .

BLOOD, 2009, 113 (13) :2895-2901

← 1 2 →